LNTH

Lantheus Holdings, Inc. is a medical imaging and radiopharmaceutical company focused on diagnostic and therapeutic applications. The company develops, manufactures, and commercializes innovative imaging agents used in nuclear medicine procedures to diagnose and treat various medical conditions. Lantheus' key products include DEFINITY for cardiac ultrasound imaging and Pylarify, a prostate-specific membrane antigen (PSMA) PET imaging agent for prostate cancer detection. The company serves hospitals, clinics, and imaging centers worldwide with specialized pharmaceutical products that enable physicians to make more informed diagnostic decisions.